Search

Your search keyword '"Francois Venter"' showing total 255 results

Search Constraints

Start Over You searched for: Author "Francois Venter" Remove constraint Author: "Francois Venter" Database OpenAIRE Remove constraint Database: OpenAIRE
255 results on '"Francois Venter"'

Search Results

1. Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV

3. Roadmap for Achieving Universal Antiretroviral Treatment

4. Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG

5. Slow and Steady But Not Related to HIV Stigma: Physical Activity in South Africans Living with HIV and Chronic Pain

6. Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection

7. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

9. Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV

10. Impact and cost-effectiveness of the national scale-up of HIV pre-exposure prophylaxis among female sex workers in South Africa: a modelling analysis

12. A Retrospective Medical Record Review to Describe Health Status and Cardiovascular Disease Risk Factors of Bus Drivers in South Africa

13. Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of HIV in Low- and Middle-Income Countries (LMICs)

14. Weight and metabolic changes after switching from tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC+DTG and TDF/FTC/efavirenz (EFV) to TDF/lamivudine (3TC)/DTG

15. Response to comments by Taramasso and colleagues on weight gain stopping/switch rules for antiretroviral clinical trials

17. Comparing Prospective Incident Severe Acute Respiratory Syndrome Coronavirus 2 Infection Rates During Successive Waves of Delta and Omicron in Johannesburg, South Africa

18. Environmental stewardship: confluence of law and religion?

19. Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial

20. What we have learned from antiretroviral treatment optimization efforts over the last 5 years?

22. Salus populi suprema lex: Godsdiensvryheid in krisistye

23. Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa

24. Pharmacokinetic and pharmacogenetic associations with dolutegravir neuropsychiatric adverse events in an African population

25. Influence of shift work on cardiovascular disease risk in Southern African long-distance truck drivers: a cross-sectional study

26. CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz

27. Corrigendum to: CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz

28. Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency Virus

32. Coronavirus Host Genomics Study: South Africa (COVIGen-SA)

35. Concentration-response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy

36. Judicial Defence of Constitutionalism in the Assessment of South Africa's International Obligations

37. Weight gain stopping/switch rules for antiretroviral clinical trials

38. Drug resistance and use of long-acting ART

39. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz

40. Patterns of Immune Activation in HIV and Non HIV Subjects and Its Relation to Cardiovascular Disease Risk

41. Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list

42. Comparative Constitutional Theory

43. Jacobsohn G and Schor M (eds) Comparative Constitutional Theory

44. Preparing for the next pandemic: Lessons from rapid scale-up of SARS-CoV-2 testing in a South African high-throughput automated HIV molecular laboratory

49. Coronavirus Disease 2019: First Data From Africa

50. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa : a modelling analysis

Catalog

Books, media, physical & digital resources